Clinical Trials & COVID-19

Health Care Professionals

NOTE: Information on this webpage is applicable to Healthcare Professionals (HCPs) only.

The CT-0508 study is sponsored by Carisma Therapeutics. It is a Phase 1, first in human clinical research study to explore the safety and tolerability of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpression in solid tumors. This study is currently taking place in the US with 5 total study locations in California, North Carolina, Pennsylvania, Tennessee, and Texas.

Primary study objective

Study Therapy & Rationale

CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with an adenoviral vector containing an anti-HER2 CAR.

Adoptive T cell–based cellular therapies have led to remarkable advances among patients with hematologic malignancies, but not in those with solid tumors. Among the multiple factors impeding T cell immunotherapy in solid tumors is the inability of T cells, including CAR-T cells, to infiltrate the microenvironment surrounding tumor cells. Macrophages, by contrast, are actively recruited into the tumor microenvironment. While macrophages contain the necessary machinery for phagocytosis and antigen presentation, macrophages in the tumor microenvironment (TME), called tumor-associated macrophages (TAMs), typically evince immunosuppressive rather than antitumor behavior. Thus, macrophages engineered to be proinflammatory may be an ideal vector to administer adoptive cellular therapy in solid tumors.

Please fill out the following form:

*Do not fill out if you are a patient interested in joining the study. Visit the to email the site closest to you.

Thank you, your submission has been received!
If you are interested in referring a patient, you can navigate to the "Refer a patient" section at the bottom the page and use the interactive map to locate and contact a nearby study site.
Oops! Something went wrong while submitting the form.

Study Overview

Study participation could last about 13 months from the screening visit and is separated into 2 groups. Study design includes the following:

Pre-infusion Period

Both Groups (7 weeks)

Infusion Period

Group 1 (Day 1, 3, & 5)

Group 2 (Day 1)

Post-infusion Period

Group 1 (Day 8 through Week 4)

Group 2 (Day 2 through Week 4)

Efficacy Follow-up and End of Study Visit

Both Groups (Weeks 8 through 52)

Key eligibility criteria

Inclusion Criteria:

Exclusion Criteria:

*Other protocol-defined Inclusion/Exclusion criteria may apply.

Contact and additional information for the CT-0508 study:

For more information, please contact Carisma Therapeutics via email at .

Send Email

Additional study information can also be found on

Refer a patient

Use the filters, map, and listing to find the nearest study clinic. You can contact the study clinic using the associated email link or phone number.

North Carolina Comprehensive Cancer Care Center

Address Location Pin
450 West Dr, Chapel Hill, NC 27599
World image icon
North Carolina
Phone icon
919-445-4208

City of Hope

Address Location Pin
1500 E. Duarte Road, Duarte, CA 91010
World image icon
California
Phone icon
626-218-0721

University of Pennsylvania Abramson Cancer Center

Address Location Pin
3400 Civic Center Boulevard, Philadelphia, PA 19104
World image icon
Pennsylvania
Phone icon
215-614-1812

MD Anderson Cancer Center

Address Location Pin
1155 Pressler St, Unit 1354, Houston, TX 77230
World image icon
Texas
Phone icon
713-792-9137

Sarah Cannon and HCA Research Institute

Address Location Pin
250 25th Ave N., Suite 307, Nashville, TN 37203
World image icon
Tennessee
Phone icon
615.524.4195